CLPT

ClearPoint is a legitimate commercial-stage neuro medtech with a differentiated franchise: the ClearPoint MRI-guided system plus the newer SmartFrame OR and Prism laser lines, and — the real long-term prize — a biologics/drug-delivery services business serving 60+ gene- and cell-therapy customers, anchored by FDA marketing authorization for the SmartFlow cannula to deliver an approved AADC gene therapy. The top line backs this up: revenue has compounded steadily ($20.6M→$24.0M→$31.4M→$37.0M) with FY2025 up +17.8%, and gross margin is a healthy 61.4%. This is not a broken business; it is a small-cap platform with genuine, durable demand and an unusually large adjacent option in becoming the 'picks-and-shovels' delivery layer for CNS gene therapies.

The problem is that none of the operating leverage has shown up, and the balance sheet got riskier in 2025. Net loss widened to -$25.5M (from -$18.9M), operating margin is -65.4%, and operating cash flow deteriorated 167% to -$23.9M of burn. The IRRAS acquisition — expanding into neurocritical care (the IRRAflow ICP/fluid-management system) — was funded with debt: long-term debt jumped +393% to $49.1M, total liabilities +405% to $69.7M, and liabilities/equity is now 2.49x against a thin $28.0M equity base and a -$217M accumulated deficit. Cash of $45.9M covers roughly two years of the current burn, but with $49M of debt now ahead of shareholders and 7.4% annual share growth, both refinancing and dilution are live risks. The 10-K's own language flags the biologics upside as entirely contingent on partners completing trials, winning approvals, and clearing reimbursement/adoption hurdles — i.e., not in ClearPoint's control.